SB 202190 (152121-30-7) is a potent and selective p38 MAP kinase inhibitor acting at the ATP site.1 Selectively inhibits the p38α and β isoforms (IC50= 50 and 100 nM for SAPK2a/p38 and SAPK2b/p38β2 respectively).2 SB 202190 effectively blocks LPS-induced gene expression in monocytes.3 Induces apoptosis.4 Cell permeable.
1) Young et al. (1997), Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site; J. Biol. Chem., 272 12116
2) Davies et al. (2000), ,i>Specificity and mechanism of action of some commonly used protein kinase inhibitors; Biochem. J., 351 95
3) Manthey et al. (1998), SB202190, a selective inhibitor of p38 mitogen-activated protein kinase, is a powerful regulator of LPS-induced mRBAs in monocytes; J. Leukoc. Biol., 64 409
4) Nemoto et al. (1998), Induction of apoptosis by SB202190 through inhibition of p38β mitogen-activated protein kinase; J. Biol. Chem., 273 16415